Johns Hopkins Scientists Designing Compounds To Fight Malaria

Chemists have developed new compounds that show promise in treating malaria by making the disease-causing parasites self-destruct.

A scientific paper about the compounds will appear in the March 12 issue of the Journal of Medicinal Chemistry, published by the American Chemical Society.

At any given time, about 300 million people suffer from malaria, and as many as 3 million of them, mostly children, will die every year. The most severe form of the infection is caused by tiny parasites called Plasmodium falciparum, which are transmitted by female mosquitos feeding on human blood.

The drug of choice to combat malaria has been chloroquine, a derivative of quinine, which comes from the bark of the Cinchona tree. But the malaria parasites began showing resistance to chloroquine nearly 40 years ago.

Chinese chemists have isolated a new anti-malarial drug from the plant Artemisia annua, which has been used for thousands of years as an herbal remedy for fever. The drug, called artemisinin, has since been proven to be effective against malaria. Chemists have developed derivatives of artemisinin, as well. But artemisinin and its derivatives remain difficult and expensive to produce, and they quickly break down in the human body.

New synthetic compounds being developed at Johns Hopkins have been shown to kill malaria parasites in test tubes and in experiments with mice. Although the synthetic compounds use the same general mechanism as artemisinin, they are not derivatives of the drug; they are a new type of compound that has a much simpler structure. Because they are simpler, they can be made in only three to five chemical steps, compared to 12 or more steps for the artemisinin derivatives.

The research is being conducted by a team of scientists led by Gary H. Posner, Scowe Professor of Chemistry in The Johns Hopkins University School of Arts and Sciences, Theresa A. Sh

Contact: Emil Venere
Johns Hopkins University

Page: 1 2 3

Related biology news :

1. Yale professor receives Johnson & Johnson Focused Giving award
2. Marian Johnson-Thompson wins 2004 Alice C. Evans Award
3. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
4. Johns Hopkins gene hunters pinpoint new cancer gene target
5. OXiGENE announces launch of ophthalmic clinical trial at The Johns Hopkins School of Medicine
6. Johns Hopkins receives $24 million from Donald W. Reynolds Foundation to study sudden cardiac death
7. Johns Hopkins researchers devise methods to evaluate disaster drills
8. Johns Hopkins scientists create forgetful mouse
9. A bed of microneedles: Johns Hopkins scientists gadget measures muscle cell force
10. Wake Forest-Johns Hopkins team discovers prostate cancer gene
11. The next generation of scientists recognized at Johns Hopkins

Post Your Comments:

(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/18/2016)... --> --> ... & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection ... border security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, ... defence & security companies in the border security ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
Cached News: